PET Scan Imaging of the Adrenal Gland Using FNP-59 Tracer
Tests a radioactive tracer PET scan to image adrenal glands in adults.
Key facts
- Who runs it
- Benjamin Viglianti
- Where
- Ann Arbor and Grand Rapids, United StatesSee the 2 sites
- Trial code
- Registry title
- Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 24 people, planned
- Started
- 1 Nov 2021
- Expected to end
- Dec 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- Dexamethasone (Group 2)
- Cosyntropin (Group 3)
- PET/CT Scan with FNP-59
- Record updated
- 5 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults for a PET scan of the adrenal glands. Some are people without known adrenal disease. Others have abnormal adrenal hormone release.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Groups 2 and 3: no known adrenal disease. Group 4: abnormal adrenal cortical hormone secretion.
- Earlier treatment
- People in Groups 2 and 3 cannot be using steroids, oral contraceptives, spironolactone, estrogen, androgen, progesterone, ACE inhibitors/ARBs, or hormone-like supplements.
Main reasons for not taking part
- Pregnancy
- Unable to do imaging
- Body weight greater than 400 lbs (181 Kg)
- Prisoners
- Unable to give own consent
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participants without any known adrenal pathology as normal controls for undergoing endocrine manipulation
- Abnormal adrenal cortical hormone secretion
Who cannot take part
- Current use of steroids, Oral contraceptives (OCP), spironolactone, estrogen, androgen, progesterone, Angiotensin-converting enzyme (ACE inhibitors)/ Angiotensin II receptor blockers (ARBs), or supplements that are hormone analogues
- Pregnancy
- Unable to do imaging
- Body weight greater than 400 lbs (181 Kg)
- Prisoners are not eligible
- Subjects unable to provide own consent are not eligible
- Known adrenal pathology
- Pregnant
Where in United States
- University of MichiganAnn Arbor, United StatesContact: James PoolTaking people
- BAMF Health Inc.Grand Rapids, United StatesContact: Jim PoolNo longer taking part
About the trial
What the trial wants to find out
This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 ([18F]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.
The 3 groups in the trial
- Dexamethasone (Group 2)Treatment being tested
Participants will undergo an FNP-59 scan on day 0 in the am. Participants will then take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production. Participants will then have a second FNP-59 scan on day 4 in the am.
Treatment: Dexamethasone (Group 2) and PET/CT Scan with FNP-59
- Cosyntropin (Group 3)Treatment being tested
Participants will undergo an FNP-59 scan on day 0 in the am. On day 4 the participant will arrive for imaging. Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
Treatment: Cosyntropin (Group 3) and PET/CT Scan with FNP-59
- Adrenal pathology (Group 4)Treatment being tested
Whole-body PET/CT scans will be done on 4 patients at 1 hr and the other 4 patients at 6 hours. All the patients will have a whole-body PET/CT scan at 3 hours.
Treatment: PET/CT Scan with FNP-59
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
- Plain-language title
- PET Scan Imaging of the Adrenal Gland Using FNP-59 TracerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 December 2025